Role of biomarkers in predicting disease severity in acute dengue and SARs-CoV-2-Infected patients

dc.contributor.authorYamasmith E.
dc.contributor.authorKinslow J.D.
dc.contributor.authorBerg M.G.
dc.contributor.authorCloherty G.A.
dc.contributor.authorMoy J.N.
dc.contributor.authorLanday A.L.
dc.contributor.authorSuputtamongkol Y.
dc.contributor.authorTantibhedhyangkul W.
dc.contributor.correspondenceYamasmith E.
dc.contributor.otherMahidol University
dc.date.accessioned2026-02-06T18:24:29Z
dc.date.available2026-02-06T18:24:29Z
dc.date.issued2026-12-01
dc.description.abstractPurpose: The early stages of both dengue infection and COVID-19 can present similarly with acute febrile illness or influenza-like symptoms, and individuals with initially mild disease may progress to more severe symptoms. We performed biomarker analysis to determine if host immune responses can predict the disease severity of both diseases. Methods: Differential immune response profiles in patient populations were compared during acute dengue or COVID-19 using a panel of 22 soluble biomarkers. Patient plasma biomarkers were measured by ELISA or the Meso Scale Discovery platform, and statistical analysis was performed using SAS software. Receiver operating characteristic (ROC) curves were created to identify the optimal cut-off values for differentially upregulated biomarkers in severe cases. Multiple logistic regression models were developed to predict disease severity using a combination of selected biomarkers, with or without demographic data, and were analyzed using GraphPad Prism software. Results: Almost all of the biomarkers were higher in dengue compared to COVID-19 patients. Comparing severe to mild dengue illness, biomarkers related to monocyte activation (IL-1β, IL-12p70, soluble CD14) and Th2 cytokines (IL-4 and IL-13) were significantly elevated. Additionally, 1,3 β-D-glucan, a biomarker related to gut barrier disruption and microbial translocation, was elevated in patients with severe dengue and emerged as a key severity biomarker. In COVID-19 patients, the chemokine CXCL10 (IP-10) was the best predictive biomarker for severity. Moreover, biomarkers related to gut mucosal barrier disruption (lipopolysaccharide-binding protein, soluble CD14, and 1,3 β-D-glucan) and neutrophil extracellular trap (NET) markers were elevated in moderate to severe COVID-19. The multiple logistic regression models predicting severity for both diseases yielded ROC curves with an excellent area under the curve (AUC) greater than 0.95 and demonstrated sensitivity, specificity, positive predictive value, and negative predictive value greater than 90%. Conclusions: Our analyses indicate that gut barrier disruption and subsequent microbial translocation are common phenomena in severe cases of dengue and COVID-19. Multiple logistic regression models using a combination of specific biomarkers have the potential to improve severity prediction.
dc.identifier.citationBMC Infectious Diseases Vol.26 No.1 (2026)
dc.identifier.doi10.1186/s12879-025-12196-4
dc.identifier.eissn14712334
dc.identifier.pmid41345556
dc.identifier.scopus2-s2.0-105026973835
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/114630
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.titleRole of biomarkers in predicting disease severity in acute dengue and SARs-CoV-2-Infected patients
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105026973835&origin=inward
oaire.citation.issue1
oaire.citation.titleBMC Infectious Diseases
oaire.citation.volume26
oairecerif.author.affiliationThe University of Texas Medical Branch at Galveston
oairecerif.author.affiliationRush University Medical Center
oairecerif.author.affiliationSiriraj Hospital
oairecerif.author.affiliationAbbott Laboratories
oairecerif.author.affiliationAbbott Diagnostics
oairecerif.author.affiliationPolice General Hospital

Files

Collections